Synapse Biomedical, Inc. Awarded GSA Schedule for NeuRx® Diaphragm Pacing System product line; device will benefit veterans with spinal cord injury (SCI) and ALS

News provided by

Aug 09, 2016, 07:30 ET

OBERLIN, Ohio, Aug. 9, 2016 /PRNewswire/ -- Synapse Biomedical (www.synapsebiomedical.com ) has been awarded a GSA Schedule 65IIA contract and is now certified to provide goods & services to the Federal government. Federal officials appreciate GSA Schedules as a means of procurement, knowing that companies on GSA Schedules have been qualified by the General Services Administration (GSA). Synapse Biomedical will place their novel NeuRx Diaphragm Pacing Systems (DPS) for use in both ALS and spinal cord injury (SCI) on GSA Advantage!^®, the government's electronic ordering system www.gsaadvantage.gov .

"This schedule opens doors for our company to continue to help veterans and service VA hospitals," stated Anthony Ignagni, CEO Synapse Biomedical, "Our unique device, the NeuRx DPS, will allow many veterans with spinal cord injury to replace or reduce their need for mechanical ventilation and its use in ALS has been shown to provide a survival benefit."

The NeuRx DPS is an FDA approved device, under a Humanitarian Device Exemption (HDE) for use in patients with high spinal cord injury (SCI) as well as ALS patients with chronic hypo-ventilation. The device has implanted in over 1800 patients to-date and is offered in 27 countries.Dr. Onders, Interim-Chairman of Surgery & Remen Chair in Surgical Innovation at University Hospitals of Cleveland and Professor of Surgery at Case Western Reserve University, stated, "DPS has consistently been shown to be safe and a preferred mode of breathing for SCI patients. Newer data shows the benefit of DPS in other respiratory compromised populations including Lou Gerhrig's disease (ALS)."

About NeuRx DPS ^® Technology

The NeuRx DPS® received FDA approval for ventilator dependency from spinal cord injury on June 17, 2008. The NeuRx DPS was approved, September 28, 2011, by the FDA for treating chronic hypoventi-lation from ALS. The NeuRx DPS^® has demonstrated that it can help people with ALS live longer and sleep better than the current standard of care, alone. For more on current indications for use, visit www.synapsebiomedical.com/products/patientInfo.shtml

Logo - http://photos.prnewswire.com/prnh/20131113/CL14319LOGO

SOURCE Synapse Biomedical Inc.